Peritransplant Ruxolitinib Administration Is Safe and Effective in Patients with Myelofibrosis: A Pilot Open-Label Study

Investigators reported results of a prospective pilot trial evaluating the safety/feasibility of peri-transplant administration of ruxolitinib for myelofibrosis treatment. Peri-HCT ruxolitinib was safe and well-tolerated with the maximum tolerated dose determined as 10 mg BID, associated with dose-dependent PK and cytokine profile.